Shopping Cart
Remove All
Your shopping cart is currently empty
GDC-0927 is a novel,non-steroidal, potent, orally bioavailable, selective estrogen receptor antagonist.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $747 | 7-10 days | 7-10 days | |
| 25 mg | $1,610 | 7-10 days | 7-10 days | |
| 50 mg | $2,570 | 7-10 days | 7-10 days |
| Description | GDC-0927 is a novel,non-steroidal, potent, orally bioavailable, selective estrogen receptor antagonist. |
| In vivo | GDC-0927, a novel and potent non-steroidal, orally bioavailable selective estrogen receptor (ER) antagonist/degrader (SERD), effectively induces tumor regression in patient-derived xenograft models of estrogen receptor-positive (ER+) breast cancer (BC). |
| Synonyms | SRN-927 |
| Molecular Weight | 461.52 |
| Formula | C28H28FNO4 |
| Cas No. | 1642297-01-5 |
| Relative Density. | 1.257 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 83.33 mg/mL (180.56 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (7.15 mM), Sonication is recommeded. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.